BOTHELL, Wash., May 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter financial results will be released after market close on Wednesday, May 10, 2023. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business update.
To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free (800) 715-9871. The conference ID number is 4014878. A webcast replay will be available approximately two hours after the call and will be archived on https://www.biolifesolutions.com/ for 90 days.
About BioLife Solutions
BioLife Solutions is a leading provider of class-defining bioproduction tools and services to the cell and gene therapy (CGT) and broader biopharma markets. Our tools facilitate basic and applied research and the commercialization of new therapies by supplying solutions that maintain the health and function of biologic source material and finished products during manufacturing, storage, and distribution. For more information, please visit www.biolifesolutions.com and follow BioLife on LinkedIn and Twitter.
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$24.34 |
Daily Change: | -0.98 -3.87 |
Daily Volume: | 1,291,323 |
Market Cap: | US$1.160B |
August 07, 2025 April 07, 2025 January 13, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load